Biology and treatment of myelodysplastic syndromes — developments in the past decade
Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases c...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1993 |
|---|
| Umfang: |
9 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Annals of hematology - 1955, 66(1993) vom: März, Seite 107-115 |
| Übergeordnetes Werk: |
volume:66 ; year:1993 ; month:03 ; pages:107-115 ; extent:9 |
| Links: |
|---|
| Katalog-ID: |
NLEJ202971740 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ202971740 | ||
| 003 | DE-627 | ||
| 005 | 20230506011244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1993 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ202971740 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Biology and treatment of myelodysplastic syndromes — developments in the past decade |
| 264 | 1 | |c 1993 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Willemze, R. |4 oth | |
| 700 | 1 | |a Fibbe, W. E. |4 oth | |
| 700 | 1 | |a Falkenburg, J. H. F. |4 oth | |
| 700 | 1 | |a Kluin-Nelemans, J. C. |4 oth | |
| 700 | 1 | |a Kluin, P. M. |4 oth | |
| 700 | 1 | |a Landegent, J. E. |4 oth | |
| 773 | 0 | 8 | |i in |t Annals of hematology |d 1955 |g 66(1993) vom: März, Seite 107-115 |w (DE-627)NLEJ18898836X |w (DE-600)1458429-3 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:1993 |g month:03 |g pages:107-115 |g extent:9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01697618 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 1993 |c 3 |h 107-115 |g 9 | ||
| matchkey_str |
article:14320584:1993----::ilgadramnomeoypatcydoedvlpe |
|---|---|
| hierarchy_sort_str |
1993 |
| publishDate |
1993 |
| allfields |
(DE-627)NLEJ202971740 DE-627 ger DE-627 rakwb eng Biology and treatment of myelodysplastic syndromes — developments in the past decade 1993 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease. Springer Online Journal Archives 1860-2002 Willemze, R. oth Fibbe, W. E. oth Falkenburg, J. H. F. oth Kluin-Nelemans, J. C. oth Kluin, P. M. oth Landegent, J. E. oth in Annals of hematology 1955 66(1993) vom: März, Seite 107-115 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:66 year:1993 month:03 pages:107-115 extent:9 http://dx.doi.org/10.1007/BF01697618 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 66 1993 3 107-115 9 |
| spelling |
(DE-627)NLEJ202971740 DE-627 ger DE-627 rakwb eng Biology and treatment of myelodysplastic syndromes — developments in the past decade 1993 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease. Springer Online Journal Archives 1860-2002 Willemze, R. oth Fibbe, W. E. oth Falkenburg, J. H. F. oth Kluin-Nelemans, J. C. oth Kluin, P. M. oth Landegent, J. E. oth in Annals of hematology 1955 66(1993) vom: März, Seite 107-115 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:66 year:1993 month:03 pages:107-115 extent:9 http://dx.doi.org/10.1007/BF01697618 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 66 1993 3 107-115 9 |
| allfields_unstemmed |
(DE-627)NLEJ202971740 DE-627 ger DE-627 rakwb eng Biology and treatment of myelodysplastic syndromes — developments in the past decade 1993 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease. Springer Online Journal Archives 1860-2002 Willemze, R. oth Fibbe, W. E. oth Falkenburg, J. H. F. oth Kluin-Nelemans, J. C. oth Kluin, P. M. oth Landegent, J. E. oth in Annals of hematology 1955 66(1993) vom: März, Seite 107-115 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:66 year:1993 month:03 pages:107-115 extent:9 http://dx.doi.org/10.1007/BF01697618 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 66 1993 3 107-115 9 |
| allfieldsGer |
(DE-627)NLEJ202971740 DE-627 ger DE-627 rakwb eng Biology and treatment of myelodysplastic syndromes — developments in the past decade 1993 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease. Springer Online Journal Archives 1860-2002 Willemze, R. oth Fibbe, W. E. oth Falkenburg, J. H. F. oth Kluin-Nelemans, J. C. oth Kluin, P. M. oth Landegent, J. E. oth in Annals of hematology 1955 66(1993) vom: März, Seite 107-115 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:66 year:1993 month:03 pages:107-115 extent:9 http://dx.doi.org/10.1007/BF01697618 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 66 1993 3 107-115 9 |
| allfieldsSound |
(DE-627)NLEJ202971740 DE-627 ger DE-627 rakwb eng Biology and treatment of myelodysplastic syndromes — developments in the past decade 1993 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease. Springer Online Journal Archives 1860-2002 Willemze, R. oth Fibbe, W. E. oth Falkenburg, J. H. F. oth Kluin-Nelemans, J. C. oth Kluin, P. M. oth Landegent, J. E. oth in Annals of hematology 1955 66(1993) vom: März, Seite 107-115 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:66 year:1993 month:03 pages:107-115 extent:9 http://dx.doi.org/10.1007/BF01697618 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 66 1993 3 107-115 9 |
| language |
English |
| source |
in Annals of hematology 66(1993) vom: März, Seite 107-115 volume:66 year:1993 month:03 pages:107-115 extent:9 |
| sourceStr |
in Annals of hematology 66(1993) vom: März, Seite 107-115 volume:66 year:1993 month:03 pages:107-115 extent:9 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Annals of hematology |
| authorswithroles_txt_mv |
Willemze, R. @@oth@@ Fibbe, W. E. @@oth@@ Falkenburg, J. H. F. @@oth@@ Kluin-Nelemans, J. C. @@oth@@ Kluin, P. M. @@oth@@ Landegent, J. E. @@oth@@ |
| publishDateDaySort_date |
1993-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ18898836X |
| id |
NLEJ202971740 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202971740</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506011244.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1993 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202971740</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biology and treatment of myelodysplastic syndromes — developments in the past decade</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Willemze, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fibbe, W. E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Falkenburg, J. H. F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kluin-Nelemans, J. C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kluin, P. M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Landegent, J. E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">66(1993) vom: März, Seite 107-115</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:66</subfield><subfield code="g">year:1993</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:107-115</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01697618</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">66</subfield><subfield code="j">1993</subfield><subfield code="c">3</subfield><subfield code="h">107-115</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ18898836X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-0584 |
| topic_title |
Biology and treatment of myelodysplastic syndromes — developments in the past decade |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r w rw w e f we wef j h f f jhf jhff j c k n jck jckn p m k pm pmk j e l je jel |
| hierarchy_parent_title |
Annals of hematology |
| hierarchy_parent_id |
NLEJ18898836X |
| hierarchy_top_title |
Annals of hematology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ18898836X (DE-600)1458429-3 |
| title |
Biology and treatment of myelodysplastic syndromes — developments in the past decade |
| spellingShingle |
Biology and treatment of myelodysplastic syndromes — developments in the past decade |
| ctrlnum |
(DE-627)NLEJ202971740 |
| title_full |
Biology and treatment of myelodysplastic syndromes — developments in the past decade |
| journal |
Annals of hematology |
| journalStr |
Annals of hematology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1993 |
| contenttype_str_mv |
zzz |
| container_start_page |
107 |
| container_volume |
66 |
| physical |
9 |
| format_se |
Elektronische Aufsätze |
| title_sort |
biology and treatment of myelodysplastic syndromes — developments in the past decade |
| title_auth |
Biology and treatment of myelodysplastic syndromes — developments in the past decade |
| abstract |
Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease. |
| abstractGer |
Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease. |
| abstract_unstemmed |
Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Biology and treatment of myelodysplastic syndromes — developments in the past decade |
| url |
http://dx.doi.org/10.1007/BF01697618 |
| remote_bool |
true |
| author2 |
Willemze, R. Fibbe, W. E. Falkenburg, J. H. F. Kluin-Nelemans, J. C. Kluin, P. M. Landegent, J. E. |
| author2Str |
Willemze, R. Fibbe, W. E. Falkenburg, J. H. F. Kluin-Nelemans, J. C. Kluin, P. M. Landegent, J. E. |
| ppnlink |
NLEJ18898836X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| up_date |
2024-07-06T09:25:13.847Z |
| _version_ |
1803821162274226176 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202971740</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506011244.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1993 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202971740</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biology and treatment of myelodysplastic syndromes — developments in the past decade</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Conclusions During the past 10 years, MDS has become a topic of considerable interest due to the development of new cytogenetic and molecular techniques and the introduction of the clinical administration of hematopoietic growth factors. The cytological and clinical classifications of the diseases comprising the syndrome are based on two main subtypes, those with a low risk of acquiring acute leukemia and those with a high risk. Which one will prove to be the simplest and most reliable classification system for the individual patient is not yet clear. Studies on clonality have shown that the myeloid cells in most of the patients studied thus far are monoclonal in nature. These methods can be used to evaluate the effect of treatment regimens. The kinetics of the in vitro growth of hematopoietic precursor cells from MDS patients is abnormal, with suboptimal colony formation. Cultures grown in the presence of certain growth factors show preferential growth of normal hematopoietic cells, which may be of clinical relevance in the future. Administration to MDS patients of hematopoietic growth factors such as GM-CSF, G-CSF, and IL-3 improves neutrophil counts in the majority of cases. The effect of erythropoietin is disappointing in most cases. At present, polyclonal hematopoiesis is rarely induced by growth factor treatment alone. More recently identified growth factors, such as MGF, might preferentially affect normal hematopoiesis at the expense of the preleukemic clones, thus changing the natural course of the disease.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Willemze, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fibbe, W. E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Falkenburg, J. H. F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kluin-Nelemans, J. C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kluin, P. M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Landegent, J. E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">66(1993) vom: März, Seite 107-115</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:66</subfield><subfield code="g">year:1993</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:107-115</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01697618</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">66</subfield><subfield code="j">1993</subfield><subfield code="c">3</subfield><subfield code="h">107-115</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| score |
7.399967 |